Wealth Enhancement Advisory Services
DNLI icon

Wealth Enhancement Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Buy
+16,467
New +$338K ﹤0.01% 2853

Other funds holding DNLI

EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
BCG
Breakwater Capital Group Paramus, New Jersey $833M AUM 22.71% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Wealth Enhancement Advisory Services's DNLI Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 16,467 shares worth $423K. The stake represents ﹤0.01% of the portfolio and ranks #2853 among its holdings.

38 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Wealth Enhancement Advisory Services held 16,467 shares of Denali Therapeutics worth $423K as of Q2 2026.
  • Denali Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2853 holding.
  • 38 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.